The role of genetic markers in the evaluation and management of thyroid nodules.
Thyroid nodules are common, with increasing incidence, but only 5% to 15% of nodules are malignant. Genetic markers should only be used as an ancillary diagnostic tool for indeterminate thyroid nodules. Veracyte Afirma may improve the diagnostic accuracy for a subset of indeterminate cytologic diagnosis. Overall clinical, imaging, and cytopathologic evaluation in addition to patient preference should guide the management of indeterminate nodules. Further multicentered and independent validation studies are needed in order to prove the efficacy of commercially available genetic markers.